Natco Pharma’s board approves rights issue worth ₹1,279 crore; check issue price, record date and more

According to a regulatory filing, the drug manufacturer’s board approved the proposal to issue 1.71 crore (or 1,70,58,082) rights equity shares, with a face value of ₹2 each.

The issue will have a rights issue price of ₹750 per rights equity share, and will include a premium of ₹748 per rights unit.

Rights issue record date and schedule

The company’s board of directors also fixed Thursday, October 1, 2026, as the record date for determining the eligibility of members for the rights issue.

The issue will open on Monday, October 12, 2026, and close on Thursday, October 22, 2026.

Furthermore, the rights issue’s will have an on-market renunciation between Monday, October 12 and Friday, October 16, 2026.

Details of the rights issue

The company will offer rights equity shares to eligible shareholders in the ratio of two rights equity shares for every 21 fully paid-up equity shares held on the record date.

“For rights equity shares being offered under this Issue, if the shareholding of any of the eligible equity shareholders is less than 21 equity shares or not in a multiple of 21, the fractional entitlement of such eligible equity shareholders shall be ignored in the computation of the rights entitlement,” the filing read.

However, Natco Pharma added that eligible shareholders whose fractional entitlements are being ignored will be given preferential consideration for the allotment of one additional rights equity share each if they apply for additional rights shares over and above their rights entitlement, “if any, subject to availability of Rights Equity Shares in the Issue post allocation towards rights entitlements applied for”.

Additionally, eligible shareholders holding less than 21 shares will have zero right entitlement in the issue.

“Such Eligible Equity Shareholders are entitled to apply for additional Rights Equity Shares and will be given preference in the allotment of one additional Rights Equity Share if such Eligible Equity Shareholders apply for the additional Rights Equity Shares. However, they cannot renounce the same in favour of third parties, and the application forms shall be non-negotiable,” Natco Pharma stated.

Natco Pharma stock performance

Shares of Natco Pharma advanced as much as 1% to hit an intraday high of ₹850.10 per unit on the National Stock Exchange (NSE) on Friday, September 25. However, it slipped into the red zone.

At around 12:20 PM, the scrip was trading 0.08% lower at ₹841.35 per equity share. The stock has jumped more than 3% in the past week but lost 3% over the month. On a year-to-date (YTD) basis, it has fallen 5%.

While the shares hit a 52-week high of ₹1,226.80 apiece on May 12, 2026, they touched a year’s low of ₹789 per unit on September 30, 2025.

Natco Pharma has a total market capitalisation of ₹15,061.35 crore as of September 25, 2026, according to data on the NSE.